Author:
London C.,Mathie T.,Stingle N.,Clifford C.,Haney S.,Klein M. K.,Beaver L.,Vickery K.,Vail D. M.,Hershey B.,Ettinger S.,Vaughan A.,Alvarez F.,Hillman L.,Kiselow M.,Thamm D.,Higginbotham M. L.,Gauthier M.,Krick E.,Phillips B.,LaDue T.,Jones P.,Bryan J.,Gill V.,Novasad A.,Fulton L.,Carreras J.,McNeill C.,Henry C.,Gillings S.
Reference28 articles.
1. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs wtih spontaneous malignancies;London;Clinical Cancer Research,2003
2. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision;London;Clinical Cancer Research,2009
3. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors;Pryer;Clinical Cancer Research,2003
4. Sunitinib: from rational design to clinical efficacy;Chow;Journal of Clinical Oncology,2007
5. Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib;Mena;Anticancer Drugs,2010
Cited by
189 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献